PSI-697 is an oral P-selectin inhibitor with an IC50 of 125 μM.

Product information

CAS Number: 851546-61-7

Molecular Weight: 367.83

Formula: C21H18ClNO3

Chemical Name: 2-[(4-chlorophenyl)methyl]-3-hydroxy-7H,8H,9H,10H-cyclohexa[h]quinoline-4-carboxylic acid

Smiles: OC1C(CC2=CC=C(Cl)C=C2)=NC2C(=CC=C3CCCCC3=2)C=1C(O)=O

InChiKey: DIEPFYNZGUUVHD-UHFFFAOYSA-N

InChi: InChI=1S/C21H18ClNO3/c22-14-8-5-12(6-9-14)11-17-20(24)18(21(25)26)16-10-7-13-3-1-2-4-15(13)19(16)23-17/h5-10,24H,1-4,11H2,(H,25,26)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : ≥ 45.8 mg/mL (124.51 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

PSI-697 inhibits the binding of a soluble human P-selectin to PSGL-1, in a reproducible concentration-dependent manner inhibiting 50% of binding at a concentration of 125 μM in vitro.

In Vivo:

PSI-697 (0-50 mg/kg; p.o.) significantly reduces the number of rolling leukocytes by 39% versus vehicle control. PSI-697 (100 mg/kg; p.o.) reduces thrombus weight by 18% relative to vehicle, without prolonging bleeding time in a rat venous thrombosis model. PSI-697 (30 mg/kg; p.o.; daily; 6 days) promotes thrombus resolution and decreases inflammation in a baboon model of venous thrombosis. PSI-697 ((30 mg/kg; i.g.; daily) decreases vein wall injury in a rat stenosis model of venous thrombosis.

Products are for research use only. Not for human use.